More than 1,800 employees at the Bern facility develop and manufacture innovative biotherapies derived from human plasma.
R&D Switzerland at a glance: We are strengthening our local R&D network to contribute to our global strategic goals.
We are proud to work in the field of rare and serious diseases and to provide therapy in many areas of treatment.
We also aim to make sure that nothing holds you back from getting the therapies you need.
We operate as one integrated global R&D organization that assembles coordinated global project teams.
CSL supports Investigator-Initiated Studies (IIS) that advance medical and scientific knowledge of CSL Behring products and the diseases they treat.
Every day at CSL Behring, we work as if someone's life depends on it, because it does.
CSL Behring biotherapies are manufactured in state-of-the-art facilities under stringent, controlled conditions.
At CSL, Diversity, Equity, and Inclusion (DEI) is at the core of our mission and who we are. It fuels our innovation day in and day out.
Whether you are early in your college education or recently completed your degree, it's never too soon to consider CSL for your Promising Future!
Popular search terms:
2020
CSL Behring is one of the best employers in Switzerland. A glimpse behind the scenes.
A potential hyperimmune treatment for COVID-19 reaches a regulatory milestone in testing its efficacy and safety.
As co-leader, CSL Behring is very actively involved in this project. The product for the clinical trial phase 3 was manufactu…
CSL Behring had a small celebration to mark the grand opening of the facility,
CSL Behring validates new production capacity in Bern.
CSL Limited (ASX:CSL; USOTC:CSLLY) today announced a reported net profit after tax of $2,103 million (1) for the 12 months en…
CSL Behring to become latest partner in BaseLaunch Phase II
One of CSL Behring's newest innovation centers in Bern, Switzerland, springs back to full life, with COVID-19 precautions in …
CSL Behring in Bern manufactures the hyperimmune for the pivotal Phase III clinical trial.
Americas
Asia Pacific
Middle East
Europe
